The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "adalimumab"

Search results for: adalimumab

First Biosimilar to Adalimumab Enters the U.S. Market After Years of Legal Battles

January 31, 2023 • By Michele B. Kaufman, PharmD, BCGP

After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, adalimumab-atto, Biosimilars, FDA, Legal, PsA Resource Center, Psoriatic Arthritis, U.S. Food and Drug Administration (FDA)

FDA Approves First Interchangeable Biosimilar to Adalimumab, Plus a Combination Drug Approved

November 17, 2021 • By Michele B. Kaufman, PharmD, BCGP

Cyltezo (adalimumab-adbm) may be interchanged for Humira (adalimumab) for all indications, according to an October decison by the FDA. The FDA has also approved a new combination of celecoxib and tramadol for pain management. ... [Read More]

Filed Under: Analgesics, Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, adalimumab-adbm, Biosimilars, celecoxib, interchangeability, Pain Management, tramadol

Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

October 14, 2021 • By Vanessa Caceres

As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis fac­tor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medi­cine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib… [Read More]

Filed Under: Conditions, Drug Updates, Safety Tagged With: adalimumab, PsA Resource Center, Psoriatic Arthritis, upadacitinib

Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate

March 9, 2021 • By Vanessa Caceres

In phase 3 clinical trial, upadacitnib proved superior to placebo and adalimumab in improving the signs and symptoms of RA in patients on stable background methotrexate.... [Read More]

Filed Under: ACR Convergence, DMARDs & Immunosuppressives, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2020, ACR Convergence 2020 – RA, adalimumab, jakinib, RA Resource Center, upadacitinib

Oxford University to Study Adalimumab as Potential COVID-19 Treatment

September 30, 2020 • By Josephine Mason & Kate Kelland

LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown… [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, COVID-19

FDA Approves the Biosimilar Hadlima (Adalimumab-bwwd)

September 16, 2019 • By Michele B. Kaufman, PharmD, BCGP

Hadlima (adalimumab-bwwd), which is biosimilar to adalimumab, is now FDA approved to treat multiple autoimmune diseases…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab-bwwd, FDA, FDA approval, Hadlima, U.S. Food and Drug Administration (FDA)

Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up

July 10, 2019 • By Lara C. Pullen, PhD

A five-year study in patients with juvenile idiopathic arthritis-associated uveitis found drug-induced disease remission did not persist once adalimumab was stopped after long-term treatment.... [Read More]

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: adalimumab, JIA, juvenile idiopathic arthritis (JIA), Uveitis

Ixekizumab vs. Adalimumab for PsA: How Do They Compare?

July 1, 2019 • By Michele B. Kaufman, PharmD, BCGP

In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, EULAR, ixekizumab, Psoriatic Arthritis

The Rescue: Moving RA Patients from Adalimumab to Baricitinib

June 25, 2019 • By Lara C. Pullen, PhD

The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…... [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: adalimumab, baricitinib, Rheumatoid Arthritis (RA), washout

Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

April 3, 2019 • By Michele B. Kaufman, PharmD, BCGP

Health Canada has approved adalimumab for treating chronic non-infectious anterior uveitis in patients 2 years and older…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, non-infectious anterior uveitis, Pediatric, Uveitis

  • 1
  • 2
  • 3
  • …
  • 34
  • Next Page »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)